PPADS
PPADS (Pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid) is a selective P2 receptor antagonist. It is commonly used in pharmacology and neuroscience research to study the role of purinergic signaling in various physiological and pathological processes.
Chemical Structure and Properties[edit | edit source]
PPADS is a derivative of pyridoxal phosphate, which is a form of vitamin B6. The chemical structure of PPADS includes an azophenyl group and two sulfonic acid groups, which contribute to its ability to selectively inhibit P2 receptors.
Mechanism of Action[edit | edit source]
PPADS functions by blocking the activity of P2 receptors, which are a class of purinergic receptors that respond to extracellular nucleotides such as ATP and ADP. By inhibiting these receptors, PPADS can modulate various cellular responses, including inflammation, pain, and neurotransmission.
Applications in Research[edit | edit source]
PPADS is widely used in experimental studies to investigate the role of purinergic signaling in different biological systems. It has been employed in research on cardiovascular diseases, neurological disorders, and immune responses. For example, PPADS has been used to study the effects of P2 receptor inhibition on ischemia-reperfusion injury in the heart and brain.
Pharmacological Effects[edit | edit source]
The pharmacological effects of PPADS are primarily due to its ability to block P2 receptors. This can lead to a reduction in inflammatory responses, modulation of pain perception, and alteration of neurotransmitter release. PPADS has also been shown to have potential therapeutic applications in conditions such as chronic pain, neurodegenerative diseases, and autoimmune disorders.
Safety and Toxicity[edit | edit source]
As with any pharmacological agent, the safety and toxicity of PPADS must be carefully evaluated. Studies have shown that PPADS can be toxic at high concentrations, and its effects can vary depending on the specific biological system being studied. Researchers must use appropriate dosages and experimental conditions to minimize potential adverse effects.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
